Recent studies have demonstrated that inhibition of PDE4D with rolipram or roflumilast can decrease the malignant properties of colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway, which is vital for tumor growth and survival. Here, PDE4D is linked to neoplasm.